Fasting News and Research

RSS

Group weight loss programs reduce risk for type 2 diabetes

The 57 million Americans currently living with "pre-diabetes" could benefit from a group weight loss program, like Weight Watchers, according to a new study published in this month's American Journal of Lifestyle Medicine. Researchers found that after a 6-month Weight Watchers group program, overweight or obese adults who attended at least two thirds of the weekly sessions, not only lost weight, but also significantly reduced fasting glucose and insulin levels - important indicators of diabetes risk.

21 May 2010

Weight Watchers group program helps obese adults lose weight, reduce glucose and insulin levels

20 May 2010

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Atherotech Inc. will exhibit its VAP® Cholesterol Test in booth #102 at the National Lipid Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 at the Sheraton Hotel and Towers in Chicago.

13 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Physical activity can reduce prevalence of metabolic syndrome, CVD risk factors

Metabolic syndrome (MetS) is made up of unhealthy cardiovascular disease (CVD) risk factors including abdominal obesity, high levels of triglycerides, low level of HDL-cholesterol, elevated blood pressure, and elevated fasting glucose level as defined by the American Heart Association/ National Heart, Lung, and Blood Institute (AHA/NHLBI).

10 May 2010

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801.

7 May 2010

Lack of physical activity and greater TV viewing time associated with wider retinal venules

It is well known that the lack of physical activity is a risk factor for cardiovascular diseases, but what part does it play in retinal vascular caliber? A team of researchers examined the association of physical activity and television viewing time with retinal vascular caliber and explored the differences in white, black, Hispanic and Chinese racial/ethnic groups.

6 May 2010

Some parts of cholesterol testing for children can be performed without fasting: Study

Physicians usually ask children to fast overnight before a cholesterol test. New research shows that this may not always be necessary.

3 May 2010

Majority of patients who appear healthy may be at risk for cardiovascular disease

Three separate studies announced today at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) examined the cardiovascular consequences of relatively healthy patients - those who were asymptomatic and not classified as hypertensive or diabetic - and found that many patients who appear healthy may still be at risk for cardiovascular disease.

3 May 2010

Highlights from AACE 19th Annual Meeting and Clinical Congress

today's highlights from the AACE Annual Meeting & Clinical Congress in Boston

24 Apr 2010

Overweight adolescent children tend to follow weight-control strategies of their parents: Study

When parents maintain a healthy body image and weight-control strategies, overweight adolescent children tend to follow their example, a new study reveals.

24 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

SpectraCell Laboratories introduces apolipoprotein E genotyping

Effective immediately, SpectraCell Laboratories now offers apolipoprotein E genotyping. This test determines a person's genetic risk for heart disease associated with the commonly studied gene called apoE, which is involved in the metabolism of cholesterol and triglycerides (fats in the blood).

22 Apr 2010

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix' internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

20 Apr 2010

Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Atherotech Inc. announced it will exhibit its VAP® Cholesterol Test in booth #1305 at Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP). The meeting takes place April 22-24, 2010, at the Metro Toronto Convention Centre in Toronto, Canada.

20 Apr 2010

Study refutes widely held belief that intentional weight loss in older adults leads to increased risk of death

A new study by researchers at Wake Forest University Baptist Medical Center is the first to refute the widely held belief that intentional weight loss in older adults leads to increased risk of death.

5 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

Personalized online resource to help Canadians achieve healthy weight loss

A Heart and Stroke Foundation survey of almost 2,000 Canadians found that 62% reported intentionally losing five or more pounds over the past five years but failed to keep the weight off. And 70% of those who were overweight or obese regained all or even more pounds after their weight-loss efforts.

1 Apr 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

Fasting News and Research

Group weight loss programs reduce risk for type 2 diabetes

Weight Watchers group program helps obese adults lose weight, reduce glucose and insulin levels

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Physical activity can reduce prevalence of metabolic syndrome, CVD risk factors

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Lack of physical activity and greater TV viewing time associated with wider retinal venules

Some parts of cholesterol testing for children can be performed without fasting: Study

Majority of patients who appear healthy may be at risk for cardiovascular disease

Highlights from AACE 19th Annual Meeting and Clinical Congress

Overweight adolescent children tend to follow weight-control strategies of their parents: Study

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

SpectraCell Laboratories introduces apolipoprotein E genotyping

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Study refutes widely held belief that intentional weight loss in older adults leads to increased risk of death

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Personalized online resource to help Canadians achieve healthy weight loss

Patients switching to Victoza experience further reductions in A1c and weight loss

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News